Page 775 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 775
662 Part V Red Blood Cells
usually resolve spontaneously, but antibiotic therapy may accelerate complement factors. Insights into the way T cells drive and control
the process. the immune reaction could lead to novels immunotherapeutic
approaches. Synthetic peptides modulating Th1 responses via regula-
tory T cells may be developed into therapeutic tools. Another option
FUTURE DIRECTIONS would be to target structures on macrophages responsible for RBC
destruction (e.g., the CD47–SIRP-α interaction). There is hope that
Future research should mainly be directed toward generation of better novel targeted therapies will replace splenectomy and even steroid
treatment options. The generation of international guidelines is still treatment of patients with AIHA.
hampered by the lack of evidence. Every effort should be made to
initiate valid comparisons of major treatment options such as steroids,
splenectomy, and rituximab, potentially through registries or ran- REFERENCES
domized trials.
Novel therapeutic options may be provided by next-generation For the complete list of references, log on to www.expertconsult.com.
anti-CD20 antibodies or antibodies against other targets such as
